Table 1 Baseline subject characteristics
From: 18F-FDG-PET/MR imaging to monitor disease activity in large vessel vasculitis
Parameter | Baseline | Follow-up | ||||
|---|---|---|---|---|---|---|
Active disease based on clinician assessment | Inactive disease based on clinician assessment | Total | Active disease based on clinician assessment | Inactive disease based on clinician assessment | Total | |
n | 17 | 7 | 24 | 6 | 10 | 16 |
Age, years | 57 ± 15 | 70 ± 10 | 61 ± 15 | 54 ± 21 | 63 ± 12 | 60 ± 16 |
Female (%) | 13 (76) | 4 (57) | 17 (71) | 5 (83) | 7 (70) | 12 (75) |
White (%) | 17 (100) | 7 (100) | 24 (100) | 6 (100) | 10 (100) | 16 (100) |
Smoking (%) | ||||||
Current | 4 (24) | 0 (0) | 4 (17) | 1 (17) | 1 (10) | 2 (13) |
Ex- | 3 (18) | 4 (57) | 7 (29) | 0 (0) | 2 (20) | 2 (13) |
Never | 10 (59) | 3 (43) | 13 (54) | 5 (83) | 7 (70) | 12 (75) |
Diabetes (%) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
Hypertension (%) | 2 (12) | 5 (71) | 7 (29) | 0 (0) | 2 (20) | 2 (13) |
Disease characteristics | ||||||
Diagnosis (%) | ||||||
GCA | 13 (76) | 1 (14) | 14 (58) | 3 (50) | 9 (90) | 12 (75) |
TAK | 4 (24) | 2 (29) | 6 (25) | 3 (50) | 1 (10) | 4 (25) |
Unspecified | 0 (0) | 4 (57) | 4 (17) | 0 (0) | 0 (0) | 0 |
Disease duration, days | 100 [39–286] | 88 [9–986] | 94 [38–360] | 444 [314–711] | 397 [225–572] | 418 [252–543] |
Immunosuppression at time of PET/MRI (%) | ||||||
Prednisolone | 9 (53) | 3 (43) | 12 (50) | 4 (67) | 10 (100) | 14 (88) |
Methotrexate | 1 (6) | 1 (14) | 3 (13) | 2 (33) | 2 (20) | 4 (25) |
MMF | 1 (6) | 0 (0) | 1 (4) | 1 (17) | 1 (10) | 2 (13) |
Tocilizumab | 0 (0) | 0 (0) | 0 | 4 (67) | 2 (20) | 7 (44) |
Nil | 7 (41) | 4 (57) | 11 (46) | 0 (0) | 0 (0) | 0 |
Duration of immunosuppression, days | 5 [0–18] | 0 [0–420] | 4 [0–19] | 190 [163–383] | 213 [180–390] | 205 [180–385] |
Clinical | ||||||
Systolic BP, mmHg | 137 ± 19 | 140 ± 21 | 138 ± 19 | 154 ± 33 | 145 ± 23 | 148 ± 27 |
Diastolic BP, mmHg | 80 ± 14 | 75 ± 9 | 79 ± 13 | 85 ± 19 | 80 ± 16 | 82 ± 17 |
Heart rate, bpm | 83 ± 11 | 86 ± 21 | 84 ± 14 | 78 ± 14 | 73 ± 15 | 75 ± 14 |
Body mass index, kg/m2 | 23.9 ± 3.9 | 28.3 ± 4.7 | 25.2 ± 4.5 | 24.1 ± 2.4 | 25.2 ± 3.5 | 25.1 ± 3.0 |
Laboratory | ||||||
Haemoglobin, g/L | 123 ± 15 | 128 ± 29 | 125 ± 18 | 133 ± 16 | 141 ± 15 | 138 ± 15 |
Leucocytes, x109/L | 10.9 ± 3.5 | 10.4 ± 3.6 | 10.7 ± 3.5 | 10.1 ± 5.1 | 8.8 ± 2.5 | 9.3 ± 3.5 |
Platelets, x109/L | 417 ± 133 | 416 ± 223 | 417 ± 159 | 320 ± 60 | 307 ± 116 | 311 ± 98 |
C-reactive protein, mg/L | 18 [2–66] | 11 [3–69] | 13 [3–63] | 1 [0-7] | 2 [1–12] | 2 [0-10] |
ESR, mm/h | 53 ± 36 | 43 ± 41 | 49 ± 37 | 13 ± 9 | 10 ± 6 | 11 ± 7 |
Creatinine, mg/dL | 0.70 ± 0.12 | 0.93 ± 0.20 | 0.77 ± 0.18 | 0.79 ± 0.16 | 0.75 ± 0.06 | 0.78 ± 0.12 |
LRG1, ng/mL | 72.2 ± 57.7 | 61.8 ± 28.3 | 69.5 ± 51.3 | 39.2 ± 18.6 | 35.7 ± 14.3 | 36.8 ± 15.2 |
Ang-2, pg/mL | 3,443 ± 1,714 | 3,107 ± 1,512 | 3,365 ± 1,646 | 2,503 ± 896 | 1,996 ± 597 | 2,154 ± 715 |
